INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Most active filers · 30d

  1. 01Kurtz George0B / 217S · 10 late217 trades$54.77M
  2. 02SPSaba Capital Management, L.P.55B / 21S · 3 late76 trades$25.87M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05CFCheng Chi Fung0B / 42S42 trades$15.33M
  6. 06RARothblatt Martine A0B / 33S33 trades$5.50M
  7. 07RJRubinstein Julie0B / 32S32 trades$5.55M
  8. 08LBLeach Bryan0B / 30S30 trades$7.97M
  9. 09AOAtay Oguzhan0B / 30S30 trades$7.55M
  10. 10JDJenkins William D Jr0B / 30S30 trades$13.38M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 99 insiders$642K
  4. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  5. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  6. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  7. SELLIBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
  8. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K

Form 4 transactions

21,638 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
19
DA
Dignan AndyPresident
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$87K
4,924 sh
Mar 4, 2026Mar 6, 2026
Page 372 of 541
← PrevNext →
traded Mar 4, 2026
+2d
SEC Form 4

Evidence

19
KP
Kozanian PanosEVP, Product Engineering
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$126K
7,002 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

19
KP
Kozanian PanosEVP, Product Engineering
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$69K
3,860 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

19
DA
Dignan AndyPresident
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$60K
3,369 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

19
LM
Lee Bryan MChief Financial Officer
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$174K
9,855 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

19
FJ
Fitzpatrick JenniferChief Legal Officer
SIONSionna Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$347K
10.3K sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$127K
612 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$70K
340 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$94K
460 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$239K
1,142 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$61K
300 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

17
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$300K
1,457 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

16
LM
Lee Bryan MChief Financial Officer
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$31K
1,756 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$866K
4,029 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$20K
100 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$20K
100 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$411K
1,883 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$41K
200 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$41K
207 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$389K
1,848 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$19K
93 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$152K
743 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$141K
697 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$136K
668 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$192K
950 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$140K
698 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$139K
699 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

13
CC
Collier CharlesPresident, Roku Media
ROKUROKU, INC
Open-market sale · 10b5-1 plan
SELL$172K
1,715 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

11
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$356K
1,685 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

11
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$264K
1,235 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

11
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$11K
53 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

9
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$185K
5,260 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

9
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$60K
1,664 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

9
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$176K
4,994 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$346K
1,645 sh
Mar 6, 2026Mar 6, 2026
traded Mar 6, 2026
+0dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$175K
800 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$395K
1,871 sh
Mar 6, 2026Mar 6, 2026
traded Mar 6, 2026
+0dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$73K
350 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$126K
570 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$67K
300 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence